Fair Value Calculator Fair Value Calculator
EN DE

SCL Science Inc (246960) Fair Value & Analysis

Healthcare · KR · Market cap 14.8B KRW

SS SCL Science Inc 246960 · KQ
Price1,699 KRW
Fair Value1,929 KRW
Upside+13.5%
Quality24/100
Watch SCL Science Inc for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 1,439 KRW – 2,879 KRW

Fair value as of: Jul 7, 2026

From 1 valuation models · updated today

Fair value updated Jul 7, 2026 — revised from 12,955 KRW to 1,929 KRW (−85.1%) since Jun 24, 2026. Share price −9.3% over the past month.

Price vs Fair Value (12 months)

4,040 KRW 1,552 KRW Fair Value 1,929 KRW Jun 2025 Jul 2026

12‑month range 1,552 KRW – 4,040 KRW · fair‑value band 1,439 KRW – 2,879 KRW · the 1,699 KRW price screens below the 1,929 KRW fair value. As of Jul 7, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

SCL Science Inc (246960) currently trades at 1,699 KRW, while our model-based Fair Value estimate is 1,929 KRW — implying the stock looks roughly 13.5% undervalued today. We read business quality at 24/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, SCL Science Inc generated revenue of 27.4B KRW at a net margin of -11.6%. Revenue grew 237.9% year over year. It earns a return on equity of -13.3%. Net debt stands at 18.3B KRW. Fundamentals as of Jul 7, 2026

Our scenario range runs from 1,439 KRW (bear case) to 2,879 KRW (bull case); at 1,699 KRW, the current price sits within that range. The share trades about 67% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at 14%, 246960 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 27.4B KRW
Revenue growth (YoY) +238%
Net margin -11.6%
Return on equity -13.3%
Free cash flow −4.6B KRW FY2025
Operating margin -8.5%
More key figures
Net debt 18.3B KRW FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.

About the company

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

SCL Science Inc reported revenue of 22.0B KRW in FY2025 versus 507M KRW in FY2021, a compound +156.7%/yr. Reported net income was −3.9B KRW in FY2025.

Revenue +156.7%/yr
FY21 507M KRW
FY22 370M KRW
FY23 1.3B KRW
FY24 4.7B KRW
FY25 22.0B KRW
Net income
FY21 −5.0B KRW
FY22 −6.0B KRW
FY23 −5.0B KRW
FY24 −3.7B KRW
FY25 −3.9B KRW

Is 246960 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "SCL Science Inc Fair Value". https://www.fairvalue-calculator.com/stock/246960

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABTT34 R$39.41 R$30.42 -23%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDTC34 R$210.63 R$24.08 -89%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $87.45 $41.02 -53%
Siemens Healthineers AG SEMHF $40.29 $47.96 +19%
GE HealthCare Technologies Inc GEHC $61.99 $48.34 -22%
DexCom, Inc DXCM $74.77 $53.93 -28%
Koninklijke Philips N.V 1PHIA €24.31 €9.97 -59%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥143.50 ¥111.50 -22%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is SCL Science Inc (246960) undervalued?
As of Jul 7, 2026, our model estimates a fair value of 1,929 KRW versus a price of 1,699 KRW — about +14% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 246960?
Our model-based fair value for SCL Science Inc is 1,929 KRW (as of Jul 7, 2026), built from audited fundamentals. The current price is 1,699 KRW.
What is the quality score of 246960?
SCL Science Inc has a Quality Score of 24/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of SCL Science Inc (246960)?
SCL Science Inc reported trailing-twelve-month revenue of about 27.4B KRW (latest available figure, as of Jul 7, 2026).
What is the net profit margin of 246960?
The net profit margin of SCL Science Inc is about -11.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.